Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 4/20 | 1.00 |
| ▸ | S100A4 | P26447 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | CASP6 | P55212 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | STAT6 | P42226 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2077926 | 0.96 | S100A4 (0.93) | PTPRCS100A4MAPTPOLBAPEX1 | |
| SCHEMBL2599501 | 0.90 | S100A4 (1.00) | PTPRCS100A4MAPTPOLBAPEX1 | |
| Anthraquinone SCHEMBL27518707 | 0.89 | S100A4 (0.79) | PTPRCS100A4MAPTPOLBAPEX1 | |
| SCHEMBL6364877 | 0.89 | S100A4 (0.79) | PTPRCS100A4MAPTPOLBAPEX1 | |
| SCHEMBL156735 | 0.89 | S100A4 (0.79) | PTPRCS100A4MAPTPOLBAPEX1 | |
| SCHEMBL32670296 | 0.89 | S100A4 (0.79) | PTPRCS100A4MAPTPOLBAPEX1 | |
| Anthraquinone SCHEMBL27736010 | 0.89 | S100A4 (0.79) | PTPRCS100A4MAPTPOLBAPEX1 | |
| Water SCHEMBL11135902 | 0.87 | S100A4 (0.77) | PTPRCS100A4MAPTPOLBAPEX1 | |
| Ammonia Solution, Strong SCHEMBL27539963 | 0.87 | S100A4 (0.77) | PTPRCS100A4MAPTPOLBAPEX1 | |
| SCHEMBL27694074 | 0.87 | S100A4 (0.77) | PTPRCS100A4MAPTPOLBAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130090355-A1 | CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2013-04-11 | — | — | US | claimed |
| WO-2011146101-A1 | CHEMICAL AGENTS FOR THE PREVENTION OR INHIBITION OF TUMOR METASTASIS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2011-11-24 | — | — | WO | claimed |
| US-20030207812-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | claimed |
| JP-2003518085-A | — | — | 2003-06-03 | — | — | JP | claimed |
| EP-1242363-A2 | CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | claimed |
| WO-2001046125-A2 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | claimed |
| US-8507162-B2 | Electrophotographic photosensitive member, process cartridge, and electrophotographic apparatus | CANON KABUSHIKI KAISHA (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20130090355-A1 | CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090355-A1 | CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2447781-B1 | Electrophotographic photosensitive member, process cartridge, and electrophotographic apparatus | CANON KK (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-20120107735-A1 | ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER, PROCESS CARTRIDGE, AND ELECTROPHOTOGRAPHIC APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-2447781-A1 | Electrophotographic photosensitive member, process cartridge, and electrophotographic apparatus | Canon Kabushiki Kaisha (JP) | 2012-05-02 | — | — | EP | disclosed |
| WO-2011146101-A1 | CHEMICAL AGENTS FOR THE PREVENTION OR INHIBITION OF TUMOR METASTASIS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2011-11-24 | — | — | WO | disclosed |
| EP-1242363-B1 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2005-11-02 | — | — | EP | disclosed |
| US-20030207812-A1 | Cd45 inhibitors | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
| EP-1242363-A2 | CD45 INHIBITORS | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2002045702-A2 | TRICYCLIC THERAPEUTICS FOR CHEMOKINE MEDIATED DISEASES | CHEMOKINE THERAPEUTICS CORPORATION (CA) | 2002-06-13 | — | — | WO | disclosed |
| WO-2001046125-A2 | CD45 INHIBITORS | ASTRAZENECA AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| US-4036838-A | Process for the production of nitro derivatives of aromatic compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207812-A1 | Cd45 inhibitors | CD74, CD2, PTPRC | PTPRC 3/4885S100A4 2288/4885MAPT 4473/4885 |
| US-20130090355-A1 | CHEMICAL AGENTS FOR THE PREVENTION OF INHIBITION OR TUMOR METASTASIS | S100A4, S100A6, S100A10 | PTPRC 507/4885S100A4 1/4885MAPT 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.